Blocking migration using sphingosine 1-phosphate receptor 1 (S1P1)-agonist FTY720 in multiple preclinical tumor models prevented tumor regression and challenged the understanding that anti-PD-1 immunotherapy primarily targets intratumoral T cells. This evidence concerns the gene PDCD1 and neoplasm.